Mekong Capital's 6.3x return on its investment in Vietnam-based pharmaceuticals player Traphaco involved turning the company's distribution model on its head, as well as supporting expansion and improving governance
China Renaissance has added dedicated healthcare and mezzanine debt strategies to its existing growth-stage private equity offering as part of efforts to more than treble its assets under management (AUM) over the next three years.
China Venture Capital Fund, a VC vehicle backed by the Chinese government, and ChinaEquity Group have jointly led a RMB670 million ($101 million) round for 3D Medicines, which focuses on personalized diagnostics and treatment for cancer.
The Everstone Group has acquired Chemopharm, a provider of medical equipment based in Malaysia.
Sabre Partners and CDC Group have co-led a $26 million Series C round for Indian home healthcare business Portea Medical.
Vietnam’s Mekong Capital has exited its 25% stake in domestic pharmaceuticals company Traphaco for about $64.5 million. It represents a gross return multiple of 6.3x for the investment.
Nissay Capital and 2020, the Japanese investment arm of Foxconn Technology Group, have invested JPY500 million ($4.4 million) in a pre-Series B round for Tokyo-based healthcare technology start-up Triple W Japan.
Goldman Sachs and China Investment Corporation (CIC) have launched a private equity fund that is seeking to raise $5 billion to invest in US companies. The initiative is part of efforts to strengthen trade relations between the two countries.
An assortment of healthcare-focused GPs – most of them in China – have emerged to leverage rising domestic consumption and nascent medical innovation. Does domain expertise mean better deal access?
AnchorDx, a China-based company that develops new clinical diagnosis products based on next-generation sequencing (NGS) technology, has raised $28 million in a Series B round led by 6 Dimensions Capital and Sijia Jianxin Fund.
The proliferation of fund managers targeting relatively focused investment segments signals a new maturity in Asian private equity. The trend will evolve in step with regional markets
EOC Pharma, a China-based cancer treatment specialist, has closed a $32 million Series B funding round led by Taikang Industry Development Fund.
Beijing-based genomics services provider Annoroad has completed a RMB700 million ($105 million) Series C round co-led by Shenzhen GTJA Investment Group and Ping An Ventures. SBCVC and SAIF Partners China also participated.
HighLight Capital has secured $250 million for its second China healthcare-focused fund, suggesting that proven sector specialists are getting traction with institutional LPs
Hony Capital has led a Series B round of funding for Quanyi Pharmacy Chain, an investment and operating platform that is intended to consolidate Chinese retail drug stores.
Beyond Ventures and Alibaba Group have led a funding round that will support the Asia expansion of Hong Kong-based genetics healthcare start-up Prenetics
Chinese healthcare-focused GP HighLight Capital, which was set up by former CDH Investments executive Steven Wang, has closed its second US dollar-denominated fund at the hard cap of $250 million.
Innovation Network Corporation of Japan (INCJ) and imaging giant Konica Minolta have completed a $1 billion joint acquisition of US-based Ambry Genetics, with a view to growing the company in Japan.
Beyond Ventures and Chinese internet giant Alibaba Group have led a $40 million funding round for Hong Kong-based genetic testing and wellness start-up Prenetics.
In 2014 J-Star bet on a pair of pioneering companies in Japan’s hospice care market. Now the resulting platform is set to dominate the still-nascent industry with high standards for care and patient dignity
China-focused PE firm Blue Ocean Capital has exited US-listed China Cord Blood Corporation (CCBC), by selling its beneficial interest in the blood bank operator to a fund sponsored by Chinese conglomerate Sanpower Group.
C-Bridge Capital, a Chinese healthcare-focused private equity firm, has appointed Abbas Hussain, who was most recently global president for pharmaceuticals and vaccines at GlaxoSmithKline (GSK), as a senior partner.
Samara Capital Partners has acquired the Indian rights to a portfolio of drug brands from Swiss pharmaceutical company Novartis.
Healthcare specialist investor OrbiMed has committed $42.5 million in Uquifa, the active pharmaceutical ingredient (API) unit of India-listed pharmaceuticals business Vivimed Labs.